Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 14
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico (JournalArticle)

Reproductive risk factors in breast cancer and genetic hormonal pathways: a gene-environment interaction in the MCC-Spain project

  • Dierssen-Sotos, Trinidad
  • Palazuelos-Calderón, Camilo
  • Jimenez-Moleon, Jose J.
  • Aragones, Nuria
  • Altzibar, Jone M
  • Castaño-Vinyals, Gemma
  • Martín-Sánchez, Vicente
  • Gómez-Acebo, Inés
  • Guevara, Marcela
  • Tardón, Adonina
  • Perez-Gomez, Beatriz
  • Amiano, Pilar
  • Moreno, Victor
  • Molina, Antonio J
  • Alonso-Molero, Jéssica
  • Moreno-Iribas, Conchi
  • Kogevinas, Manolis
  • Pollan-Santamaria, Marina
  • Llorca, Javier
BACKGROUND: Reproductive factors are well known risk factors for breast cancer; however, little is known about how genetic variants in hormonal pathways interact with that relationship. METHODS: One thousand one hundred thirty nine cases of breast cancer in women and 1322 frequency-matched controls were compared. Genetic variants in hormonal pathways (identified in the Kyoto Encyclopedia of Genes and Genomes) were screened according to their relationship with breast cancer using the Cochran-Armitage statistic. Information on reproductive factors was obtained using a face-to-face questionnaire. The interaction among the selected genetic variants and reproductive factors was tested with logistic regression. RESULTS: Concerning C allele in rs2229712, compared to nulliparity in non-carriers the ORs for 1-2 and > 2 deliveries were 0.48 (0.28-0.81) and 0.34 (0.19-0.59), and in C carriers they were 0.92 (0.42-1.98) and 0.71 (0.31-1.61). Similar results were found in women carrying the C allele in rs1269851. Carriers of Allele T in rs35652107 and allele C in rs6018027 had the delivery number effect more pronounced. CONCLUSIONS: The number of deliveries had a dose-response protective effect on breast cancer; women carrying C allele in rs2229712 did not benefit from this protective effect.
Repisalud
Publication Artículo científico (JournalArticle)

Colorectal cancer, sun exposure and dietary vitamin D and calcium intake in the MCC-Spain study

  • Vallès, Xavier
  • Alonso, María Henar
  • López-Caleya, Juan Francisco
  • Díez-Obrero, Virginia
  • Dierssen-Sotos, Trinidad
  • Lope Carvajal, Virginia
  • Molina-Barceló, Ana
  • Chirlaque, María Dolores
  • Jimenez-Moleon, Jose J.
  • Fernández Tardón, Guillermo
  • Castilla Catalán, Jesús
  • Amiano, Pilar
  • Capelo, Rocío
  • Castaño-Vinyals, Gemma
  • Guinó, Elisabet
  • Molina de la Torre, Antonio José
  • Moreno-Iribas, Conchi
  • Perez-Gomez, Beatriz
  • Aragones, Nuria
  • Llorca, Javier
  • Martín, Vicente
  • Kogevinas, Manolis
  • Pollan-Santamaria, Marina
  • Moreno, Victor
OBJECTIVES: To explore the association of colorectal cancer with environmental solar radiation and sun exposure behavior, considering phenotypic variables (eye color, hair color and skin phenotype), dietary intake of vitamin D and calcium, and socio-demographic factors. STUDY DESIGN: Multicenter population-based frequency matched case-control study in Spain (MCC-Spain), with 2140 CRC cases and 3950 controls. METHODS: Data were obtained through personal interviews using a structured epidemiological questionnaire that included socio-demographic data, residential history, environmental exposures, behavior, phenotypic and dietary information. An environmental-lifetime sun exposure score was constructed combining residential history and average daily solar radiation, direct and diffuse. Logistic regression was used to explore the association between different variables. A structural equation model was used to verify the associations of the conceptual model. RESULTS: We found a lower risk of CRC in subjects frequently exposed to sunlight during the previous summer and skin burning due to sun exposure. No association was observed in relation to the residential solar radiation scores. Subjects with light eye or light hair colors had a lower risk of CRC that those with darker colors. Dietary calcium and vitamin D were also protective factors, but not in the multivariate model. The structural equation model analysis suggested that higher sun exposure was associated with a decreased risk of CRC, as well as dietary intake of calcium and vitamin D, and these factors are correlated among themselves and with environmental solar radiation and skin phenotypes. CONCLUSION: The results agree with previous observations that sun exposure, dietary vitamin D and calcium intake, and serum 25(OH)D concentration reduce the risk of CRC and indicate that these factors may be relevant for cancer prevention.
Repisalud
Publication Artículo científico (JournalArticle)

Validating a breast cancer score in Spanish women. The MCC-Spain study

  • Dierssen-Sotos, Trinidad
  • Gómez-Acebo, Inés
  • Palazuelos, Camilo
  • Fernandez-Navarro, Pablo L
  • Altzibar, Jone M
  • González-Donquiles, Carmen
  • Ardanaz, Eva
  • Bustamante, Mariona
  • Alonso-Molero, Jéssica
  • Vidal, Carmen
  • Bayo-Calero, Juan
  • Tardón, Adonina
  • Salas, Dolores
  • Marcos-Gragera, Rafael
  • Moreno, Victor
  • Rodríguez-Cundín, Paz
  • Vinyals, Gemma Castaño
  • Ederra, María
  • Vilorio-Marqués, Laura
  • Amiano, Pilar
  • Perez-Gomez, Beatriz
  • Aragones, Nuria
  • Kogevinas, Manolis
  • Pollan-Santamaria, Marina
  • Llorca, Javier
A breast-risk score, published in 2016, was developed in white-American women using 92 genetic variants (GRS92), modifiable and non-modifiable risk factors. With the aim of validating the score in the Spanish population, 1,732 breast cancer cases and 1,910 controls were studied. The GRS92, modifiable and non-modifiable risk factor scores were estimated via logistic regression. SNPs without available genotyping were simulated as in the aforementioned 2016 study. The full model score was obtained by combining GRS92, modifiable and non-modifiable risk factor scores. Score performances were tested via the area under the ROC curve (AUROC), net reclassification index (NRI) and integrated discrimination improvement (IDI). Compared with non-modifiable and modifiable factor scores, GRS92 had higher discrimination power (AUROC: 0.6195, 0.5885 and 0.5214, respectively). Adding the non-modifiable factor score to GRS92 improved patient classification by 23.6% (NRI = 0.236), while the modifiable factor score only improved it by 7.2%. The full model AUROC reached 0.6244. A simulation study showed the ability of the full model for identifying women at high risk for breast cancer. In conclusion, a model combining genetic and risk factors can be used for stratifying women by their breast cancer risk, which can be applied to individualizing genetic counseling and screening recommendations.
Repisalud
Publication Artículo científico (JournalArticle)

Pigmentation phototype and prostate and breast cancer in a select Spanish population-A Mendelian randomization analysis in the MCC-Spain study

  • Gómez-Acebo, Inés
  • Dierssen-Sotos, Trinidad
  • Palazuelos, Camilo
  • Fernandez-Navarro, Pablo L
  • Castaño-Vinyals, Gemma
  • Alonso-Molero, Jéssica
  • Urtiaga, Carmen
  • Fernández-Villa, Tania
  • Ardanaz, Eva
  • Rivas-Del-Fresno, Manuel
  • Molina-Barceló, Ana
  • Jimenez-Moleon, Jose J.
  • García-Martínez, Lidia
  • Amiano, Pilar
  • Rodríguez-Cundín, Paz
  • Moreno, Victor
  • Perez-Gomez, Beatriz
  • Aragones, Nuria
  • Kogevinas, Manolis
  • Pollan-Santamaria, Marina
  • Llorca, Javier
INTRODUCTION: Phototype has been associated with an increased risk of prostate cancer, and it is yet unknown if it is related to other hormone-dependent cancers, such as breast cancer or whether this association could be considered causal. METHODS: We examined the association between the phototype and breast and prostate cancers using a Mendelian randomization analysis. We studied 1,738 incident cases of breast cancer and another 817 cases of prostate cancer. To perform a Mendelian randomization analysis on the phototype-cancer relationship, a genetic pigmentation score was required that met the following criteria: (1) the genetic pigmentation score was associated with phototype in controls; (2) the genetic pigmentation score was not associated with confounders in the relationship between phototype and cancer, and (3) the genetic pigmentation score was associated with cancer only through its association with phototype. Once this genetic score is available, the association between genetic pigmentation score and cancer can be identified as the association between phototype and cancer. RESULTS: The association between the genetic pigmentation score and phototype in controls showed that a higher genetic pigmentation score was associated with fair skin, blond hair, blue eyes and the presence of freckles. Applying the Mendelian randomization analysis, we verified that there was no association between the genetic pigmentation score and cancers of the breast and prostate. CONCLUSIONS: Phototype is not associated with breast or prostate cancer.
Repisalud
Publication Artículo científico (JournalArticle)

Cohort profile: the MCC-Spain follow-up on colorectal, breast and prostate cancers: study design and initial results

  • Alonso-Molero, Jéssica
  • Molina, Antonio J
  • Jimenez-Moleon, Jose J.
  • Perez-Gomez, Beatriz
  • Martín, Vicente
  • Moreno, Victor
  • Amiano, Pilar
  • Ardanaz, Eva
  • de Sanjose, Silvia
  • Salcedo, Inmaculada
  • Fernández-Tardón, Guillermo
  • Alguacil, Juan
  • Salas, Dolores
  • Marcos-Gragera, Rafael
  • Chirlaque, María-Dolores
  • Aragones, Nuria
  • Castaño-Vinyals, Gemma
  • Pollan-Santamaria, Marina
  • Kogevinas, Manolis
  • Llorca, Javier
PURPOSE: Since 2016, the multicase-control study in Spain (MCC-Spain) has focused towards the identification of factors associated with cancer prognosis. Inception cohorts of patients with colorectal, breast and prostate cancers were assembled using the incident cases originally recruited. PARTICIPANTS: 2140 new cases of colorectal cancer, 1732 of breast cancer and 1112 of prostate cancer were initially recruited in 12 Spanish provinces; all cancers were incident and pathologically confirmed. Follow-up was obtained for 2097 (98%), 1685 (97%) and 1055 (94.9%) patients, respectively. FINDINGS TO DATE: Information gathered at recruitment included sociodemographic factors, medical history, lifestyle and environmental exposures. Biological samples were obtained, and 80% of patients were genotyped using a commercial exome array. The follow-up was performed by (1) reviewing medical records; (2) interviewing the patients by phone on quality of life; and (3) verifying vital status and cause of death in the Spanish National Death Index. Ninety-seven per cent of recruited patients were successfully followed up in 2017 or 2018; patient-years of follow-up were 30 914. Most colorectal cancers (52%) were at clinical stage II or lower at recruitment; 819 patients died in the follow-up and the 5-year survival was better for women (74.4%) than men (70.0%). 71% of breast cancers were diagnosed at stages I or II; 206 women with breast cancer died in the follow-up and the 5-year survival was 90.7%. 49% of prostate cancers were diagnosed at stage II and 32% at stage III; 119 patients with prostate cancer died in the follow-up and the 5-year survival was 93.7%. FUTURE PLANS: MCC-Spain has built three prospective cohorts on highly frequent cancers across Spain, allowing to investigate socioeconomic, clinical, lifestyle, environmental and genetic variables as putative prognosis factors determining survival of patients of the three cancers and the inter-relationship of these factors.
Repisalud
Publication Artículo científico (JournalArticle)

Use of non-steroidal anti-inflammatory drugs and risk of breast cancer: The Spanish Multi-Case-control (MCC) study

  • Dierssen-Sotos, Trinidad
  • Gómez-Acebo, Inés
  • de Pedro, María
  • Perez-Gomez, Beatriz
  • Servitja, Sonia
  • Moreno, Victor
  • Amiano, Pilar
  • Fernandez-Villa, Tania
  • Barricarte, Aurelio
  • Tardón, Adonina
  • Diaz-Santos, Marian
  • Peiró-Pérez, Rosana
  • Marcos-Gragera, Rafael
  • Lope Carvajal, Virginia
  • Gràcia-Lavedan, Esther
  • Alonso, María Henar
  • Michelena-Echeveste, Maria Jesus
  • Garcia-Palomo, Andrés
  • Guevara, Marcela
  • Castaño-Vinyals, Gemma
  • Aragones, Nuria
  • Kogevinas, Manolis
  • Pollan-Santamaria, Marina
  • Llorca, Javier
BACKGROUND: The relationship between non-steroidal antiinflammatory drug (NSAID) consumption and breast cancer has been repeatedly studied, although the results remain controversial. Most case-control studies reported that NSAID consumption protected against breast cancer, while most cohort studies did not find this effect. Most studies have dealt with NSAIDs as a whole group or with specific drugs, such aspirin, ibuprofen, or others, but not with NSAID subgroups according to the Anatomical Therapeutic Chemical Classification System; moreover, scarce attention has been paid to their effect on different tumor categories (i.e.: ductal/non-ductal, stage at diagnosis or presence of hormonal receptors). METHODS: In this case-control study, we report the NSAID - breast cancer relationship in 1736 breast cancer cases and 1895 healthy controls; results are reported stratifying by the women's characteristics (i.e.: menopausal status or body mass index category) and by tumor characteristics. RESULTS: In our study, NSAID use was associated with a 24 % reduction in breast cancer risk (Odds ratio [OR] = 0.76; 95 % Confidence Interval [CI]: 0.64-0.89), and similar results were found for acetic acid derivatives, propionic acid derivatives and COXIBs, but not for aspirin. Similar results were found in postmenopausal and premenopausal women. NSAID consumption also protected against hormone + or HER2+ cancers, but not against triple negative breast cancers. The COX-2 selectivity showed an inverse association with breast cancer (i.e. OR < 1), except in advanced clinical stage and triple negative cancers. CONCLUSION: Most NSAIDs, but not aspirin, showed an inverse association against breast cancer; this effect seems to be restricted to hormone + or HER2+ cancers.
Repisalud
Publication Artículo científico (JournalArticle)

Dietary Inflammatory Index, Dietary Non-Enzymatic Antioxidant Capacity, and Colorectal and Breast Cancer Risk (MCC-Spain Study)

  • Obón-Santacana, Mireia
  • Romaguera, Dora
  • Gràcia-Lavedan, Esther
  • Molinuevo, Amaia
  • Molina-Montes, Esther
  • Shivappa, Nitin
  • Hebert, James R
  • Tardón, Adonina
  • Castaño-Vinyals, Gemma
  • Moratalla, Ferran
  • Guinó, Elisabet
  • Marcos-Gragera, Rafael
  • Azpiri, Mikel
  • Gil, Leire
  • Olmedo-Requena, Rocío
  • Lozano-Lorca, Macarena
  • Alguacil, Juan
  • Fernández-Villa, Tania
  • Martín, Vicente
  • Molina, Antonio J
  • Ederra, María
  • Moreno-Iribas, Conchi
  • Perez-Gomez, Beatriz
  • Aragones, Nuria
  • Castelló Pastor, Adela
  • Huerta, José María
  • Dierssen-Sotos, Trinidad
  • Gómez-Acebo, Inés
  • Molina-Barceló, Ana
  • Pollan-Santamaria, Marina
  • Kogevinas, Manolis
  • Moreno, Victor
  • Amiano, Pilar
Inflammation and antioxidant capacity have been associated with colorectal and breast cancer. We computed the dietary inflammatory index (DII®), and the total dietary non-enzymatic antioxidant capacity (NEAC) and associated them with colorectal and breast cancer risk in the population-based multi case-control study in Spain (MCC-Spain). We included 1852 colorectal cancer and 1567 breast cancer cases, and 3447 and 1486 population controls, respectively. DII score and NEAC were derived using data from a semi-quantitative validated food frequency questionnaire. Unconditional logistic regression models were used to estimate odds ratios (OR) and 95% confidence intervals (95%CI) for energy-adjusted DII (E-DII), and a score combining E-DII and NEAC. E-DII was associated with colorectal cancer risk (OR = 1.93, highest quartile versus lowest, 95%CI:1.60-2.32; p-trend: <0.001); this increase was observed for both colon and rectal cancer. Less pronounced increased risks were observed for breast cancer (OR = 1.22, highest quartile versus lowest, 95%CI:0.99-1.52, p-trend: >0.10). The combined score of high E-DII scores and low antioxidant values were associated with colorectal cancer risk (OR = 1.48, highest quartile versus lowest, 95%CI: 1.26-1.74; p-trend: <0.001), but not breast cancer. This study provides evidence that a pro-inflammatory diet is associated with increased colorectal cancer risk while findings for breast cancer were less consistent.
Repisalud
Publication Artículo científico (JournalArticle)

Agreement among Mediterranean Diet Pattern Adherence Indexes: MCC-Spain Study

  • Olmedo-Requena, Rocío
  • González-Donquiles, Carmen
  • Dávila-Batista, Verónica
  • Romaguera, Dora
  • Castelló Pastor, Adela
  • Molina de la Torre, Antonio José
  • Amiano, Pilar
  • Dierssen-Sotos, Trinidad
  • Guevara, Marcela
  • Fernández-Tardón, Guillermo
  • Lozano-Lorca, Macarena
  • Alguacil, Juan
  • Peiró, Rosana
  • Huerta, José María
  • Gràcia-Lavedan, Esther
  • Aragones, Nuria
  • Fernández-Villa, Tania
  • Solans, Marta
  • Gómez-Acebo, Inés
  • Castaño-Vinyals, Gemma
  • Kogevinas, Manolis
  • Pollan-Santamaria, Marina
  • Martín, Vicente
There are many different methods used to measure the degree of adherence to a Mediterranean diet (MD), limiting comparison and interpretation of their results. The concordance between different methodologies has been questioned and their evaluation recommended. The aim of this study was to evaluate the agreement among five indexes that measure adherence to a Mediterranean dietary pattern. The study population included healthy adults selected in the Multi-Case Control Spain (MCC-Spain) study recruited in 12 provinces. A total of 3640 controls were matched to cases by age and sex. To reach the aim, the following scores of adherence to a Mediterranean dietary pattern were calculated: Mediterranean diet score (MDS), alternative Mediterranean diet (aMED), relative Mediterranean diet (rMED), dietary score (DS) and literature-based adherence score (LBAS). The relative frequency of subjects with a high level of adherence to a MD varied from 22% (aMED index) to 37.2% (DS index). Similarly, a high variability was observed for the prevalence of a low level of MD: from 24% (rMED) to 38.4% (aMED). The correlation among MDS, aMED and rMED indexes was moderate, except for MDS and aMED with a high coefficient of correlation 0.75 (95% CI 0.74⁻0.77). The Cohen's Kappa coefficient among indexes showed a moderate⁻fair concordance, except for MDS and aMED with a 0.56 (95% CI 0.55⁻0.59) and 0.67 (95% CI 0.66⁻0.68) using linear and quadratic weighting, respectively. The existing MD adherence indexes measured the same, although they were based on different constructing algorithms and varied in the food groups included, leading to a different classification of subjects. Therefore, concordance between these indexes was moderate or low.
Repisalud
Publication Artículo científico (JournalArticle)

Epidemiology of non-steroidal anti-inflammatory drugs consumption in Spain. The MCC-Spain study

  • Gómez-Acebo, Inés
  • Dierssen-Sotos, Trinidad
  • de Pedro, María
  • Perez-Gomez, Beatriz
  • Castaño-Vinyals, Gemma
  • Fernández-Villa, Tania
  • Palazuelos-Calderón, Camilo
  • Amiano, Pilar
  • Etxeberria, Jaione
  • Benavente, Yolanda
  • Fernández-Tardón, Guillermo
  • Salcedo-Bellido, Inmaculada
  • Capelo, Rocío
  • Peiró, Rosana
  • Marcos-Gragera, Rafael
  • Huerta, José María
  • Tardón, Adonina
  • Barricarte, Aurelio
  • Altzibar, Jone M
  • Alonso-Molero, Jéssica
  • Dávila-Batista, Verónica
  • Aragones, Nuria
  • Pollan-Santamaria, Marina
  • Kogevinas, Manolis
  • Llorca, Javier
BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used despite their risk of gastrointestinal bleeding or cardiovascular events. We report the profile of people taking NSAIDs in Spain, and we include demographic factors, health-related behaviours and cardiovascular disease history. METHODS: Four thousand sixtyparticipants were selected using a pseudorandom number list from Family Practice lists in 12 Spanish provinces. They completed a face-to-face computerized interview on their NSAID consumption, demographic characteristics, body mass index, alcohol and tobacco consumption and medical history. In addition, participants completed a self-administered food-frequency and alcohol consumption questionnaire. Factors associated with ever and current NSAID consumption were identified by logistic regression. RESULTS: Women consumed more non-aspirin NSAIDs (38.8% [36.7-41.0]) than men (22.3 [20.5-24.2]), but men consumed more aspirin (11.7% [10.3-13.2]) than women (5.2% [4.3-6.3]). Consumption of non-aspirin NSAIDs decrease with age from 44.2% (39.4-49.1) in younger than 45 to 21.1% (18.3-24.2) in older than 75, but the age-pattern for aspirin usage was the opposite. Aspirin was reported by about 11% patients, as being twice as used in men (11.7%) than in women (5.2%); its consumption increased with age from 1.7% (< 45 years old) to 12.4% (≥75 years old). Aspirin was strongly associated with the presence of cardiovascular risk factors or established cardiovascular disease, reaching odds ratios of 15.2 (7.4-31.2) in women with acute coronary syndrome, 13.3 (6.2-28.3) in women with strokes and 11.1 (7.8-15.9) in men with acute coronary syndrome. Participants with cardiovascular risk factors or diseases consumed as much non-aspirin NSAID as participants without such conditions. CONCLUSIONS: Non-aspirin NSAIDs were more consumed by women and aspirin by men. The age patterns of aspirin and non-aspirin NSAIDs were opposite: the higher the age, the lower the non-aspirin NSAIDs usage and the higher the aspirin consumption. People with cardiovascular risk factors or diseases consumed more aspirin, but they did not decrease their non-aspirin NSAIDs usage.
Repisalud
Publication Artículo científico (JournalArticle)

The Use of Antihypertensive Medication and the Risk of Breast Cancer in a Case-Control Study in a Spanish Population: The MCC-Spain Study

  • Gómez-Acebo, Inés
  • Dierssen-Sotos, Trinidad
  • Palazuelos, Camilo
  • Perez-Gomez, Beatriz
  • Lope Carvajal, Virginia
  • Tusquets, Ignasi
  • Alonso, María Henar
  • Moreno, Victor
  • Amiano, Pilar
  • Molina de la Torre, Antonio José
  • Barricarte, Aurelio
  • Tardón, Adonina
  • Camacho, Antonio
  • Peiró-Pérez, Rosana
  • Marcos-Gragera, Rafael
  • Muñoz, Montse
  • Michelena-Echeveste, Maria Jesus
  • Ortega Valin, Luis
  • Guevara, Marcela
  • Castaño-Vinyals, Gemma
  • Aragones, Nuria
  • Kogevinas, Manolis
  • Pollan-Santamaria, Marina
  • Llorca, Javier
INTRODUCTION: The evidence on the relationship between breast cancer and different types of antihypertensive drugs taken for at least 5 years is limited and inconsistent. Furthermore, the debate has recently been fueled again with new data reporting an increased risk of breast cancer among women with a long history of use of antihypertensive drugs compared with nonusers. METHODS: In this case-control study, we report the antihypertensive drugs-breast cancer relationship in 1,736 breast cancer cases and 1,895 healthy controls; results are reported stratifying by the women's characteristics (i.e., menopausal status or body mass index category) tumor characteristics and length of use of antihypertensive drugs. RESULTS: The relationship among breast cancer and use of calcium channel blockers (CCB) for 5 or more years had odds ratio (OR) = 1.77 (95% CI, 0.99 to 3.17). Stratifying by BMI, the OR increased significantly in the group with BMI ≥ 25 (OR 2.54, 95% CI, 1.24 to 5.22). CCBs were even more strongly associated with more aggressive tumors, (OR for invasive tumors = 1.96, 95% CI = 1.09 to 3.53; OR for non ductal cancers = 3.97, 95% CI = 1.73 to 9.05; OR for Erbb2+ cancer = 2.97, 95% CI: 1.20 to 7.32). On the other hand, premenopausal women were the only group in which angiotensin II receptor blockers may be associated with breast cancer (OR = 4.27, 95% CI = 1.32 to 13.84) but this could not be identified with any type or stage. Use of angiotensin-converting-enzyme inhibitors, beta blockers and diuretics were not associated with risk. CONCLUSIONS: In this large population-based study we found that long term use of calcium channel blockers is associated with some subtypes of breast cancer (and with breast cancer in overweight women).
Repisalud
Publication Artículo científico (JournalArticle)

Quality of Life in a Cohort of 1078 Women Diagnosed with Breast Cancer in Spain: 7-Year Follow-Up Results in the MCC-Spain Study

  • Alonso-Molero, Jéssica
  • Dierssen-Sotos, Trinidad
  • Gómez-Acebo, Inés
  • Fernandez de Larrea-Baz, Nerea
  • Guevara, Marcela
  • Amiano, Pilar
  • Castaño-Vinyals, Gemma
  • Fernández-Villa, Tania
  • Moreno, Victor
  • Bayo, Juan
  • Molina-Barceló, Ana
  • Fernández-Ortíz, María
  • Suarez-Calleja, Claudia
  • Marcos-Gragera, Rafael
  • Castells, Xavier
  • Gil-Majuelo, Leire
  • Ardanaz, Eva
  • Perez-Gomez, Beatriz
  • Kogevinas, Manolis
  • Pollan-Santamaria, Marina
  • Llorca, Javier
Breast cancer is the most frequent cause of tumors and net survival is increasing. Achieving a higher survival probability reinforces the importance of studying health-related quality of life (HR-QoL). The main aim of this work is to test the relationship between different sociodemographic, clinical and tumor-intrinsic characteristics, and treatment received with HR-QoL measured using SF-12 and the FACT/NCCN (National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy) Breast Symptom Index (FBSI). Women with breast cancer recruited between 2008 and 2013 and followed-up until 2017-2018 in a prospective cohort answered two HR-QoL surveys: the SF-12 and FBSI. The scores obtained were related to woman and tumor characteristics using linear regression models. The telephone survey was answered by 1078 women out of 1685 with medical record follow-up (64%). Increases in all three HR-QoL scores were associated with higher educational level. The score differences between women with university qualifications and women with no schooling were 5.43 for PCS-12, 6.13 for MCS-12 and 4.29 for FBSI. Histological grade at diagnosis and recurrence in the follow-up displayed a significant association with mental and physical HR-QoL, respectively. First-line treatment received was not associated with HR-QoL scores. On the other hand, most tumor characteristics were not associated with HR-QoL. As breast cancer survival is improving, further studies are needed to ascertain if these differences still hold in the long run.
Repisalud
Publication Artículo científico (JournalArticle)

Flavonoids and the Risk of Gastric Cancer: An Exploratory Case-Control Study in the MCC-Spain Study

  • Vitelli-Storelli, Facundo
  • Molina, Antonio José
  • Zamora-Ros, Raúl
  • Fernández-Villa, Tania
  • Roussou, Vasiliki
  • Romaguera, Dora
  • Aragones, Nuria
  • Obón-Santacana, Mireia
  • Guevara, Marcela
  • Gómez-Acebo, Inés
  • Fernández-Tardón, Guillermo
  • Molina-Barceló, Ana
  • Olmedo-Requena, Rocío
  • Capelo, Rocío
  • Chirlaque, María-Dolores
  • Perez-Gomez, Beatriz
  • Moreno, Victor
  • Castilla Catalán, Jesús
  • Rubín-García, María
  • Pollan-Santamaria, Marina
  • Kogevinas, Manolis
  • Lera, Juan Pablo Barrio
  • Martín, Vicente
Several epidemiological studies have investigated the association between the dietary flavonoid intake and gastric cancer (GC) risk; however, the results remain inconclusive. Investigating the relationship between the different classes of flavonoids and the histological types and origin of GC can be of interest to the research community. We used data from a population-based multi-case control study (MCC-Spain) obtained from 12 different regions of Spain. 2700 controls and 329 GC cases were included in this study. Odds ratios (ORs) were calculated using the mixed effects logistic regression considering quartiles of flavonoid intakes and log2. Flavonoid intake was associated with a lower GC risk (ORlog2 = 0.76; 95% CI = 0.65-0.89; ORq4vsq1 = 0.60; 95%CI = 0.40-0.89; ptrend = 0.007). Inverse and statistically significant associations were observed with anthocyanidins, chalcones, dihydroflavonols and flavan-3-ols. The isoflavanoid intake was positively associated with higher cancer risk, but without reaching a statistical significance. In general, no differences were observed in the GC risk according to the location and histological type. The flavonoid intake seems to be a protective factor against GC within the MCC-study. This effect may vary depending on the flavonoid class but not by the histological type and location of the tumor. Broader studies with larger sample size and greater geographical variability are necessary.
Repisalud
Publication Artículo científico (JournalArticle)

The RS4939827 polymorphism in the SMAD7 GENE and its association with Mediterranean diet in colorectal carcinogenesis

  • Alonso-Molero, Jéssica
  • González-Donquiles, Carmen
  • Palazuelos, Camilo
  • Fernández-Villa, Tania
  • Ramos, Elena
  • Pollan-Santamaria, Marina
  • Aragones, Nuria
  • Llorca, Javier
  • Henar Alonso, M.
  • Tardón, Adonina
  • Amiano, Pilar
  • Jimenez-Moleon, Jose J.
  • Peiró Pérez, Rosana
  • Capelo, Rocío
  • Molina, Antonio J
  • Acebo, Ines Gomez
  • Guevara, Marcela
  • Perez-Gomez, Beatriz
  • Lope Carvajal, Virginia
  • Huerta, José María
  • Castaño-Vinyals, Gemma
  • Kogevinas, Manolis
  • Moreno, Victor
  • Martín, Vicente
BACKGROUND: The objective of our investigation is to study the relationship between the rs4939827 SNP in the SMAD7 gene, Mediterranean diet pattern and the risk of colorectal cancer. METHODS: We examined 1087 cases of colorectal cancer and 2409 population controls with available DNA samples from the MCC-Spain study, 2008-2012. Descriptive statistical analyses, and multivariate logistic mixed models were performed. The potential synergistic effect of rs4939827 and the Mediterranean diet pattern was evaluated with logistic regression in different strata of of adherence to the Mediterranean diet and the genotype. RESULTS: High adherence to Mediterrenean diet was statistically significantly associated with colorectal cancer risk. A decreased risk for CRC cancer was observed for the CC compared to the TT genotype (OR = 0.65 and 95% CI = 0.51-0.81) of the rs4939827 SNP Also, we could show an association between the Mediterranean diet pattern (protective factor) and rs4939827. Although the decreased risk for the CC genotype was slightly more pronounced in subjects with high adherence to Mediterrenean diet, there was no statistically significant synergistic effect between genotype CC and adherence to the Mediterranean dietary pattern factors. CONCLUSION: The SMAD7 gene and specifically the allele C could be protective for colorectal cancer. An independent protective association was also observed between high adherence Mediterranean diet pattern and CRC risk. Findings form this study indicate that high adherence to Mediterranean diet pattern has a protective role for CRC cancer probably involving the Tumor Growth Factor- β pathway in this cancer.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Effect of mistimed eating patterns on breast and prostate cancer risk (MCC-Spain Study)

  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Espinosa, Ana|||0000-0001-7399-3267
  • Castelló, Adela|||0000-0002-1308-9927
  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • Guevara, Marcela|||0000-0001-9242-6364
  • Martín, Vicente|||0000-0003-0552-2804
  • Amiano, Pilar
  • Alguacil, Juan|||0000-0003-2703-9725
  • Peiro, Rosana
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Costas, Laura
  • Fernández-Tardon, Guillermo|||0000-0002-7680-158X
  • Jimenez, Jose Juan
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Llorca, Javier|||0000-0001-8569-861X
  • Moreno-Iribas, Conchi|||0000-0001-6537-0131
  • Fernández-Villa, Tania|||0000-0002-9049-3026
  • Oribe, Madalen
  • Aragonés, Nuria
  • Papantoniou, Kyriaki|||0000-0002-0340-9659
  • Pollán, Marina|||0000-0002-4328-1565
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Romaguera, Dora|||0000-0002-5762-8558
Modern life involves mistimed sleeping and eating patterns that in experimental studies are associated with adverse health effects. We assessed whether timing of meals is associated with breast and prostate cancer risk taking into account lifestyle and chronotype, a characteristic correlating with preference for morning or evening activity. We conducted a population-based case-control study in Spain, 2008-2013. In this analysis we included 621 cases of prostate and 1,205 of breast cancer and 872 male and 1,321 female population controls who had never worked night shift. Subjects were interviewed on timing of meals, sleep and chronotype and completed a Food Frequency Questionaire. Adherence to the World Cancer Research Fund/American Institute of Cancer Research recommendations for cancer prevention was examined. Compared with subjects sleeping immediately after supper, those sleeping two or more hours after supper had a 20% reduction in cancer risk for breast and prostate cancer combined (adjusted Odds Ratio [OR] = 0.80, 95%CI 0.67-0.96) and in each cancer individually (prostate cancer OR = 0.74, 0.55-0.99; breast cancer OR = 0.84, 0.67-1.06). A similar protection was observed in subjects having supper before 9 pm compared with supper after 10 pm. The effect of longer supper-sleep interval was more pronounced among subjects adhering to cancer prevention recommendations (OR both cancers= 0.65, 0.44-0.97) and in morning types (OR both cancers = 0.66, 0.49-0.90). Adherence to diurnal eating patterns and specifically a long interval between last meal and sleep are associated with a lower cancer risk, stressing the importance of evaluating timing in studies on diet and cancer. What's new? Evidence shows that long-term disruption of endogenous circadian rhythms may be associated with cancer. The effects of mistimed sleeping and eating patterns that come with modern life are however less clear. This large Spanish population-based study examined whether meal timing and sleep patterns are associated with the two most common nightshift-related cancers. Adherence to a more diurnal eating pattern, and specifically an early supper and a long interval between last meal and sleep were associated with a lower breast and prostate cancer risk, stressing the importance of evaluating circadian rhythms in diet and cancer studies and revisiting recommendations for prevention.